article thumbnail

Philips launches Duo Venous Stent System for Treatment of Symptomatic Venous Outflow Obstruction

DAIC

and an investigator in the VIVID study , which contributed to the device’s FDA approval – successfully used the Duo Venous Stent System for the first time outside of a clinical trial. Duo Hybrid has a distinct integrated design that combines multiple zones of differing mechanical properties into a single stent [3].

Stents 105
article thumbnail

Risk factors, prevention, and therapy of intraluminal stent thrombosis in frozen elephant trunk prostheses—what we know so far

Frontiers in Cardiovascular Medicine

In this phenomenon, a thrombus forms within the lumen of the stent graft component of the frozen elephant trunk prosthesis and puts the patient at risk for downstream embolization with visceral or lower limb ischemia. The long-term efficiency of these prophylactic and therapeutic measures has yet to be proven.

Stents 59
article thumbnail

SMT Publishes Trial Results for Supraflex Cruz Stent

DAIC

Smits and a distinguished team of international researchers, the trial compares the performance of SMT's biodegradable-polymer sirolimus-eluting Supraflex Cruz stent with the biodegradable-polymer Ultimaster Tansei * stent in patients with high bleeding risk (HBR) undergoing abbreviated dual antiplatelet therapy (DAPT).

Stents 52
article thumbnail

Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis Among Patients With Post-Thrombotic Syndrome: The Multicenter, Multinational, Randomized, Open-Label ARIVA Trial

Circulation

BACKGROUND:In patients with post-thrombotic syndrome, stent recanalization of iliofemoral veins or the inferior vena cava can restore venous patency and improve functional outcomes. The risk of stent thrombosis is particularly increased during the first 6 months after intervention.

article thumbnail

Medtronic Releases Atherectomy Studies at VIVA 2024

DAIC

In the DA+DCB arm, there was a trend toward higher stent-free patency through 12 months (79.1% versus 68.1%, · P=0.09) and a significantly lower provisional stenting rate (9.5% 3,4 bailout stenting rates were low following atherectomy in both observational studies (9.3% versus 21.1%, P =0.014). 3 · One-year rates of TLR (16.6%

Stent 52
article thumbnail

Prolocor, Slingshot Bioscience Publish Paper on Prognostic Tool to Help Assess Thrombosis Risk

DAIC

"Clinicians need better tools to guide decision making on the choice of antiplatelet therapy in coronary artery disease patients, particularly after coronary stenting. The Prolocor pFCG test will be an important asset as we tailor antiplatelet therapies to balance thrombotic and bleeding risk" said Dominick J.

article thumbnail

Clinical outcomes and aortic remodeling after Castor single-branched stent-graft implantation for type B aortic dissections involving left subclavian artery

Frontiers in Cardiovascular Medicine

BackgroundThe left subclavian artery (LSA) can be intentionally covered by a stent graft to acquire adequate landing zones for a proximal entry tear near the LSA during thoracic endovascular aortic repair (TEVAR). The Castor single-branched stent graft is designed to treat type B aortic dissection (TBAD) to retain the LSA during TEVAR.

Stents 52